Skip to content
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
You are currently viewing Psychedelic Therapy could reduce Anxiety, Distress among Patients with Cancer

Psychedelic Therapy could reduce Anxiety, Distress among Patients with Cancer

  • Post author:Olly PP
  • Post published:September 27, 2022
  • Post category:Industry News
Tags: Home News, Industry Media

Read more articles

Previous PostPsilocybin-Assisted Psychotherapy Treatment with Alcohol Use Disorder: A Randomized Clinical Trial
Next PostThe Psychedelic Remedy for Chronic Pain

You Might Also Like

Read more about the article Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

January 19, 2022
Read more about the article Study finds psilocybin repairs brain cell damage associated with depression

Study finds psilocybin repairs brain cell damage associated with depression

July 21, 2021
Read more about the article Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

December 30, 2016

Recent Posts

  • Expansion of Drug Discovery and a Promising Pipeline
  • Albert Labs Announces Private Placement
  • Letter of Intent (LOI) for First-In-Human studies with iNGENÅ« CRO
  • Albert Labs Provides Corporate Update
  • Psychedelic Therapy isn’t Fringe Anymore

Recent Comments

    Innovative mental health medicines for patients with unmet needs

    • Legal Disclaimer
    • Privacy Policy
    • Modern Slavery Statement
    • Cookie Policy
    • Legal Disclaimer
    • Privacy Policy
    • Modern Slavery Statement
    • Cookie Policy

    © 2022 Albert Labs. All Rights Reserved

    • About
    • Team
    • Clinical Trials
    • KRN-101
    • Investing
    • Press & Updates
    • Contact
    • About
    • Team
    • Clinical Trials
    • KRN-101
    • Investing
    • Press & Updates
    • Contact
    Twitter Linkedin Youtube Envelope
    CSE:ABRT
    FSE: VB50
    CSE:ABRT
    FSE: VB50

    About Albert Labs

    We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

    If you would like support or more information around making an investment, please contact investing@albertlabs.com

    Twitter Linkedin Youtube Envelope

    Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

    • This field is for validation purposes and should be left unchanged.

    Twitter
    Youtube
    Linkedin
    Instagram
    Envelope
    Twitter
    Youtube
    Linkedin
    Instagram
    Envelope

    By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.